CD276 and neoplasm: These studies provide the first preclinical evidence that B7H3.CAR EBVSTs can overcome the challenges of heterogeneous tumor antigen expression and antigen escape, demonstrating potent and durable efficacy against solid tumors expressing a spectrum of B7-H3 levels.